Finally, wehighlight promising therapeutic developments, including Bruton Tyrosine Kinase(BTK) inhibitors and CAR T-cell therapies, with the former representing aparadigm shift in the potential of targeting MS progression beyond focalinflammation. Here, BTK is linked to myeloid sarcoma.